Arvinas Inc   Report issue

For profit Phase 1
Founded: New Haven CT United States (2013)

Organization Overview

First Clinical Trial
2019
NCT03888612
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Arvinas Androgen Receptor, Inc. | Arvinas Inc

Active Ingredients

Drugs in Phase 1 Trials (3)

arv-110 (1 trial)

arv-471 (1 trial)

arv-766 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3